Project Grant R44CA265639

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...

This $191,064 federal Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) supports a Phase II clinical trial of the drug combination avutometinib plus defactinib for the treatment of rare, aggressive forms of thyroid cancer. The trial is being conducted by the Sloan-Kettering Institute for Cancer Research, a leading non-profit cancer research organization in New York. The study aims to evaluate the efficacy of this drug combination in treating...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $371,070 to Resonant Therapeutics, Inc. to develop a novel nectin-targeting antibody-drug conjugate (ADC) for the treatment of ovarian cancer. The funding will be used to refine the target patient population, determine the optimal payload, and establish preclinical dosing for the ADC. This represents an important advancement, as current ADC treatments for ovarian cancer are...

This $849,648 federal Project Grant award from the Food and Drug Administration's (FDA) Research program (CFDA 93.103) supports a pilot Phase II clinical study of the dual PI3K and HDAC inhibitor drug fimepinostat for the treatment of Cushing's disease. The study, led by the University of California, Los Angeles (UCLA), aims to assess the safety and efficacy of fimepinostat in 20 subjects with new, persistent, or recurrent Cushing's disease over a 4-week treatment period. The study has two...

The National Cancer Institute (NCI) awarded a $662,682 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, San Diego (UCSD) to conduct research on improving treatment outcomes for gastrointestinal stromal tumors (GIST) driven by KIT mutations. The key objectives are to: Assess the safety, tolerability, and efficacy of combining the tyrosine kinase inhibitor imatinib with the potassium channel blocker 4-AP in a Phase 1 neoadjuvant clinical...

The National Cancer Institute (NCI) awarded a $658,336 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Rarecyte, Inc. to develop an "ORION2" instrument that will enable highly multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis. The key products and services to be delivered under this 3-year grant, which runs from June 1, 2025 to May 31, 2028, include: Developing an adaptive imaging system with automated control over...

The National Cancer Institute awarded Oncotrap Inc. a $400,000 Project Grant to develop an aptamer-directed IgG1-Fc drug conjugate (AFDC) platform for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to validate the ability of the APTPDAC aptamer to selectively kill PDAC cells and create a potent AFDC targeting PDAC cells. Additionally, the project will evaluate the in vivo anti-tumor efficacy of the AFDC in PDAC mouse models and identify the target cell surface...

This $400,000 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports Senex Biotechnology Inc.'s research to develop a novel nanoparticle formulation of the mediator kinase inhibitor SNX631-6 for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy upon intraperitoneal (IP) administration, compared to oral delivery of the drug. Key activities...

This $267,298 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research by the Dana-Farber Cancer Institute to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive and poorly understood form of kidney cancer. The project aims to evaluate the sensitivity of TRCC cell lines and preclinical models to CDK4/6 inhibition, both as a monotherapy and in...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $172,193 to the Dana-Farber Cancer Institute (DFCI) to conduct research aimed at improving the diagnosis and treatment of translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer. The key objectives of the research are to: 1) Develop methods to characterize the activity of transcription factors that drive TRCC progression, 2) Build predictive metabolic...